Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$5.15 CAD
Change Today +0.10 / 1.98%
Volume 9.6K
As of 3:59 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

887 Great Northern Way

Suite 250

Vancouver, BC V5T 4T5


Phone: 604-707-7000

Fax: 604-707-7001

QLT Inc., a biotechnology company, is engaged in the development and commercialization of ocular products that address the unmet medical needs of patients and clinicians worldwide. QLT091001 – Synthetic Retinoid Program The company develops QLT091001, a synthetic retinoid compound for the potential treatment of certain age-related and inherited retinal degenerative diseases. The company is in the process of evaluating QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). In 2013, the company met with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), including an end-of-phase II meeting with the FDA, with a goal to progress QLT091001 for the treatment of certain inherited retinal diseases into pivotal trials in 2014. In 2011, the United States Patent and Trademark Office issued Patent No. 7,951,841, a key patent related to this program, covering various methods of use of QLT091001 in the treatment of diseases associated with an endogenous 11-cis-retinal deficiency, expiring on July 27, 2027, including the period of patent term adjustment. QLT091001 for the treatment of Impaired Dark Adaptation (IDA): In 2013, the company initiated a Phase IIa proof-of-concept randomized, multi-center, parallel-group, placebo-controlled trial of QLT091001 in adult subjects with IDA, a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights. The trial is designed to evaluate the safety profile and effects of QLT091001 on impaired dark adaptation time, glare recovery time and low luminance low contrast best corrected visual acuity. Research and Development As of December 31, 2013, the company’s research and development expenses were $18.5 million. Regulations The research and development, preclinical studies and clinical trials, and ultimately, the manufacturing, marketing and labeling of the company’s products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries. History QLT Inc. was formed in 1981 under the laws of the Province of British Columbia.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QLT:CN C$5.15 CAD +0.10

QLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QLT.
View Industry Companies

Industry Analysis


Industry Average

Valuation QLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QLT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at